M. Kovacek

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

B. Nilsson, G. Juliusson, M. Cragg, 2015, Cancer cell.

A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo.

F. Zhan, G. Tricot, Ye Yang, 2013, Cancer cell.

A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia

G. Juliusson, M. Jerkeman, S. Ek, 2018, npj Precision Oncology.

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

V. Jiang, B. Frendéus, I. Teige, 2022, Journal of Hematology & Oncology.

Abstract 936: Targeting TNFR2 for cancer immunotherapy: Ligand blocking depletors versus receptor agonists

M. Cragg, S. Beers, B. Frendéus, 2020 .

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

B. Nilsson, G. Juliusson, M. Cragg, 2015, Cancer cell.